NKTR

Nektar Therapeutics (NKTR)

Nektar Therapeutics

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NKTR

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/10	05 : 20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NKTR	Nektar Therapeutics
2024/05/10	05 : 15	PR Newswire (US)	Nektar Therapeutics Reports First Quarter 2024 Financial Results	NASDAQ:NKTR	Nektar Therapeutics
2024/05/03	07 : 00	PR Newswire (US)	Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets	NASDAQ:NKTR	Nektar Therapeutics
2024/03/23	03 : 00	PR Newswire (US)	Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	NASDAQ:NKTR	Nektar Therapeutics
2024/03/06	07 : 11	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:NKTR	Nektar Therapeutics
2024/03/05	23 : 00	PR Newswire (US)	Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	NASDAQ:NKTR	Nektar Therapeutics
2024/03/05	06 : 20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NKTR	Nektar Therapeutics
2024/03/05	06 : 15	PR Newswire (US)	Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results	NASDAQ:NKTR	Nektar Therapeutics
2024/03/04	22 : 40	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NKTR	Nektar Therapeutics
2024/03/04	22 : 30	PR Newswire (US)	Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX	NASDAQ:NKTR	Nektar Therapeutics
2024/02/28	08 : 00	PR Newswire (US)	Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference	NASDAQ:NKTR	Nektar Therapeutics
2024/02/27	08 : 00	PR Newswire (US)	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets	NASDAQ:NKTR	Nektar Therapeutics
2024/02/23	10 : 19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/02/23	10 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/02/23	10 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/02/21	05 : 55	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/02/21	05 : 51	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/02/21	05 : 50	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/02/17	07 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NKTR	Nektar Therapeutics
2024/02/15	07 : 03	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:NKTR	Nektar Therapeutics
2024/02/14	22 : 50	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:NKTR	Nektar Therapeutics
2024/01/11	06 : 25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NKTR	Nektar Therapeutics
2024/01/04	08 : 00	PR Newswire (US)	Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA	NASDAQ:NKTR	Nektar Therapeutics
2023/12/16	08 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2023/12/16	08 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2023/12/16	08 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2023/12/16	02 : 18	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NKTR	Nektar Therapeutics
2023/12/12	08 : 00	PR Newswire (US)	Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting	NASDAQ:NKTR	Nektar Therapeutics
2023/11/28	06 : 55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NKTR	Nektar Therapeutics
2023/11/21	11 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics